253 related articles for article (PubMed ID: 8174202)
1. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
2. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
3. Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.
Chen TL; Erlichman C
Cancer Chemother Pharmacol; 1992; 30(5):370-6. PubMed ID: 1380407
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
6. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
7. ICI D1694 and idoxuridine: a synergistic antitumor combination.
Pressacco J; Hedley DW; Erlichman C
Cancer Res; 1994 Jul; 54(14):3772-8. PubMed ID: 8033097
[TBL] [Abstract][Full Text] [Related]
8. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
[TBL] [Abstract][Full Text] [Related]
9. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
[TBL] [Abstract][Full Text] [Related]
10. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
11. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors.
Van der Wilt CL; Pinedo HM; Smid K; Peters GJ
Cancer Res; 1992 Sep; 52(18):4922-8. PubMed ID: 1516048
[TBL] [Abstract][Full Text] [Related]
12. Novel chemical strategies for thymidylate synthase inhibition.
Gmeiner WH
Curr Med Chem; 2005; 12(2):191-202. PubMed ID: 15638735
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
14. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition.
Stout TJ; Stroud RM
Structure; 1996 Jan; 4(1):67-77. PubMed ID: 8805515
[TBL] [Abstract][Full Text] [Related]
15. Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Pressacco J; Erlichman C
Biochem Pharmacol; 1993 Dec; 46(11):1989-97. PubMed ID: 8267649
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic and biochemical implications of combining AZT and AG-331.
Pressacco J; Mitrovski B; Erlichman C
Cancer Chemother Pharmacol; 1995; 35(5):387-90. PubMed ID: 7850919
[TBL] [Abstract][Full Text] [Related]
17. Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S]leucovorin combination therapy for breast cancer.
Tominaga T; Toi M; Shirasaka T
Anticancer Res; 1993; 13(6B):2425-7. PubMed ID: 8135478
[TBL] [Abstract][Full Text] [Related]
18. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Mullany S; Svingen PA; Kaufmann SH; Erlichman C
Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
